» Articles » PMID: 22276816

Sinus Augmentation Using RhBMP-2/ACS in a Mini-pig Model: Relative Efficacy of Autogenous Fresh Particulate Iliac Bone Grafts

Overview
Specialty Dentistry
Date 2012 Jan 27
PMID 22276816
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Implant dentistry in the posterior maxilla often requires bone augmentation. The gold standard, autogenous bone graft, requires additional surgery with associated morbidity, while bone biomaterials may not support relevant bone formation. Recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS), however, induces significant, clinically relevant bone formation in several settings including the maxillary sinus floor.

Objective: The objective of this study was to compare local bone formation and osseointegration following maxillary sinus augmentation using rhBMP-2/ACS or a particulate autogenous cancellous bone graft obtained from the iliac crest in conjunction with immediate placement of dental implants.

Materials And Methods: Bilateral sinus augmentation using an extraoral approach including rhBMP-2 (0.43 mg/ml)/ACS or the autogenous bone graft, alternated between left and right sinus cavities in five adult male Yucatan mini-pigs, was performed. Two 12-mm dental implants were inserted into the sinus wall protruding approximately 8 mm into the sinus cavity. Surgical sites were closed and sutured in layers; block biopsies collected for histometric analysis at 8 weeks.

Results: rhBMP-2/ACS induced bone of significantly greater and consistent quality compared with the iliac crest autogenous bone graft; bone density averaging 51.9 ± 3.0% vs. 32.9 ± 2.5% (P = 0.01). However, there were only numerical differences in augmented bone height (9.3 ± 0.5 vs. 8.6 ± 0.7 mm) and bone-implant contact (37.4 ± 3.0% vs. 30.7 ± 5.9%) between treatments.

Conclusion: rhBMP-2/ACS induces bone of superior quality compared with an iliac crest particulate autogenous cancellous bone graft when used for maxillary sinus augmentation, and should perhaps be considered the new standard for this indication.

Citing Articles

Sinus augmentation with poly(ε)caprolactone-β tricalcium phosphate scaffolds, mesenchymal stem cells and platelet rich plasma for one-stage dental implantation in minipigs.

Nam J, Almansoori A, Kwon O, Seo Y, Kim B, Kim Y J Periodontal Implant Sci. 2023; 53(3):218-232.

PMID: 37336521 PMC: 10315254. DOI: 10.5051/jpis.2300660033.


MiR-20a promotes osteogenic differentiation in bone marrow-derived mesenchymal stem/stromal cells and bone repair of the maxillary sinus defect model in rabbits.

Wang Y, Peng Z, Sun Z, Pan Y, Ai H, Mai Z Front Bioeng Biotechnol. 2023; 11:1127908.

PMID: 37091341 PMC: 10113429. DOI: 10.3389/fbioe.2023.1127908.


The recent advances in scaffolds for integrated periodontal regeneration.

Woo H, Cho Y, Tarafder S, Lee C Bioact Mater. 2021; 6(10):3328-3342.

PMID: 33817414 PMC: 7985477. DOI: 10.1016/j.bioactmat.2021.03.012.


Maxillary Sinus Floor Augmentation with Autogenous Bone Graft Alone Compared with Alternate Grafting Materials: a Systematic Review and Meta-Analysis Focusing on Histomorphometric Outcome.

Starch-Jensen T, Deluiz D, Bruun N, Tinoco E J Oral Maxillofac Res. 2020; 11(3):e2.

PMID: 33262881 PMC: 7644272. DOI: 10.5037/jomr.2020.11302.


Comparison of recombinant human bone morphogenetic protein-2-infused absorbable collagen sponge, recombinant human bone morphogenetic protein-2-coated tricalcium phosphate, and platelet-rich fibrin-mixed tricalcium phosphate for sinus augmentation....

Kim C, Ju M, Kim B J Dent Sci. 2019; 12(3):205-212.

PMID: 30895052 PMC: 6400000. DOI: 10.1016/j.jds.2017.01.003.